학술논문

Helical tomotherapy with simultaneous integrated boost dose painting for the treatment of synchronous primary cancers involving the head and neck.
Document Type
article
Source
The British journal of radiology. 87(1040)
Subject
Humans
Carcinoma
Squamous Cell
Head and Neck Neoplasms
Neoplasms
Multiple Primary
Tomography
Spiral Computed
Biopsy
Disease-Free Survival
Treatment Outcome
Radiotherapy Dosage
Radiotherapy Planning
Computer-Assisted
Feasibility Studies
Patient Selection
Aged
Aged
80 and over
Middle Aged
Female
Male
Radiotherapy
Intensity-Modulated
Bioengineering
Biomedical Imaging
Dental/Oral and Craniofacial Disease
Cancer
Rare Diseases
Clinical Sciences
Nuclear Medicine & Medical Imaging
Language
Abstract
ObjectiveTo demonstrate the feasibility of helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) for the treatment of synchronous primary cancers arising from the head and neck.Methods14 consecutive patients with histologically proven squamous cell carcinoma of the head and neck were determined to have a second primary cancer in the upper aerodigestive tract on further evaluation and were treated with HT using simultaneous integrated boost IMRT. Megavoltage CT scans were acquired daily as part of an image-guided registration protocol. Concurrent platinum-based systemic therapy was given to nine patients (64%).ResultsHT resulted in durable local control in 21 of the 28 primary disease sites irradiated, including a complete clinical and radiographic response initially observed at 17 of the 20 sites with gross tumour. The mean displacements to account for interfraction motion were 2.44 ± 1.25, 2.92 ± 1.09 and 2.31 ± 1.70 mm for the medial-lateral (ML), superior-inferior (SI) and anteroposterior (AP) directions, respectively. Table shifts of >3 mm occurred in 19%, 20% and 22% of the ML, SI and AP directions, respectively. The 2-year estimates of overall survival, local-regional control and progression-free survival were 58%, 73% and 60%, respectively.ConclusionThe effectiveness of HT for the treatment of synchronous primary cancers of the head and neck was demonstrated.Advances in knowledgeHT is a feasible option for synchronous primary cancers of the head and neck and can result in long-term disease control with acceptable toxicity in appropriately selected patients.